Sat.Mar 16, 2024 - Fri.Mar 22, 2024

Remove gene-therapy-fda-approval
article thumbnail

FDA approves Orchard’s Lenmeldy gene therapy for MLD

Pharmaceutical Technology

The US FDA has granted approval to Orchard Therapeutics' Lenmeldy for specific forms of metachromatic leukodystrophy (MLD).

article thumbnail

After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US

Fierce Pharma

Kyowa Kirin’s bet on Orchard Therapeutics has paid off, furnishing the Japanese drugmaker with a newly approved gene therapy in the U.S. | The FDA on Monday gave a thumbs up to Lenmeldy as the first gene therapy in the U.S. for kids with certain types of metachromatic leukodystrophy (MLD).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Orchard follows buyout with FDA approval of rare disease gene therapy

Bio Pharma Dive

clearance of Lenmeldy, for a rare and inherited metabolic disease, triggers an additional payout related to Kyowa Kirin’s recent deal to acquire the once high-flying gene therapy developer.

article thumbnail

Orchard Wins FDA Approval for First Gene Therapy for Rare Pediatric Disease

BioSpace

Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.

article thumbnail

Orchard Sets $4.25M US Price for Gene Therapy Lenmeldy on Heels of Approval

BioSpace

Two days after winning FDA approval, Orchard Therapeutics on Wednesday provided its U.S. launch plans for metachromatic leukodystrophy gene therapy Lenmeldy, which has a wholesale acquisition cost of $4.25 million for the one-time treatment.

article thumbnail

AGC Biologics to manufacture first FDA approved gene therapy for metachromatic leukodystrophy

BioPharma Reporter

Food and Drug Administration has cleared AGC Biologicsâ Milan site to begin manufacturing of Orchard Therapeuticsâ Lenmeldy (atidarsagene autotemcel), a gene therapy for early-onset metachromatic leukodystrophy (MLD).

article thumbnail

This week in drug discovery (18-22 March) 

Drug Discovery World

This has been an interesting week for cell and gene therapies, with two landmark FDA approvals, two significant fundraising efforts and potentially ground-breaking study results in glioblastoma. The post This week in drug discovery (18-22 March) appeared first on Drug Discovery World (DDW).